BAYRY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:16):

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...

Stats
आज की मात्रा	235 784
औसत मात्रा	2.07M
बाजार मूल्य	29.24B
EPS	$0 ( 2024-03-05 )
अगली कमाई की तारीख	( $0 ) 2024-05-09
Last Dividend	$0.632 ( 2023-05-02 )
Next Dividend	$0 ( N/A )
P/E	-9.30
ATR14	$0.00500 (0.07%)

मात्रा सहसंबंध

लंबा: 0.02 (neutral)

छोटा: 0.16 (neutral)

Signal:(50.382) Neutral

Bayer Aktiengesellschaft सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Bayer Aktiengesellschaft सहसंबंध - मुद्रा/वस्त्र

0.84
( strong )

0.85
( strong )

0.00
( neutral )

0.85
( strong )

-0.61
( weak negative )

-0.87
( strong negative )

Bayer Aktiengesellschaft वित्तीय

Annual	2023
राजस्व:	$47.64B
सकल लाभ:	$27.89B (58.54 %)
EPS:	$-2.99

FY	2023
राजस्व:	$47.64B
सकल लाभ:	$27.89B (58.54 %)
EPS:	$-2.99

FY	2022
राजस्व:	$50.74B
सकल लाभ:	$30.87B (60.84 %)
EPS:	$4.22

Financial Reports:

No articles found.

Bayer Aktiengesellschaft Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.632 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bayer Aktiengesellschaft Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.23 - low (7.68%) | Divividend Growth Potential Score: 2.39 - Decrease likely (52.29%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.320	2001-04-25
Last Dividend	$0.632	2023-05-02
Next Dividend	$0	N/A
Payout Date	2023-05-15
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	1.58	--
Div. Sustainability Score	3.23
Div.Growth Potential Score	2.39
Div. Directional Score	2.81	--

Next Divdend (Est)
(2025-03-31)

$0.640 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.58

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
REMYY	Ex Dividend Junior	2023-09-26	Annually	0.00%
FBAK	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
VONOY	Ex Dividend Junior	2023-05-26	Annually	0.00%
LNNGY	Ex Dividend Knight	2023-08-23	Annually	0.00%
CIHKY	Ex Dividend Knight	2023-07-03	Annually	0.00%
SGAPY	Ex Dividend Knight	2023-08-02	Semi-Annually	0.00%
GLAPY	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
AILLM	Ex Dividend Knight	2023-07-14	Quarterly	0.00%
MYBF	Ex Dividend Knight	2023-10-04	Quarterly	0.00%
CODYY	Ex Dividend Knight	2023-06-08	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0617	1.500	-1.235	-1.852	[0 - 0.5]
returnOnAssetsTTM	-0.0238	1.200	-0.795	-0.954	[0 - 0.3]
returnOnEquityTTM	-0.0816	1.500	-2.02	-3.03	[0.1 - 1]
payoutRatioTTM	-0.809	-1.000	-8.09	8.09	[0 - 1]
currentRatioTTM	1.259	0.800	8.70	6.96	[1 - 3]
quickRatioTTM	0.784	0.800	-0.0946	-0.0757	[0.8 - 2.5]
cashRatioTTM	0.201	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.355	-1.500	4.08	-6.11	[0 - 0.6]
interestCoverageTTM	0.595	1.000	-0.891	-0.891	[3 - 30]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.05	2.00	8.97	10.00	[0 - 20]
debtEquityRatioTTM	1.332	-1.500	4.67	-7.01	[0 - 2.5]
grossProfitMarginTTM	0.585	1.000	3.58	3.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0333	1.000	-1.333	-1.333	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.109	1.000	-0.507	-0.507	[0.2 - 2]
assetTurnoverTTM	0.386	0.800	-0.759	-0.607	[0.5 - 2]
Total Score				3.23

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.30	1.000	-0.333	0	[1 - 100]
returnOnEquityTTM	-0.0816	2.50	-1.297	-3.03	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.05	2.00	9.32	10.00	[0 - 30]
dividendYielPercentageTTM	9.49	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
payoutRatioTTM	-0.809	1.500	-8.09	8.09	[0 - 1]
pegRatioTTM	0.243	1.500	-1.711	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.100	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.39

Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.